Global private investment firm Bridgewest Group, recognised for developing innovative companies in life sciences, software, and deep tech, has launched new Contract Development and Manufacturing Organisation (CDMO) focused on sterile injectable drug products. This follows the recent announcement on the acquisition of the Perth sterile injectable manufacturing plant from Pfizer.

The newly acquired facility and team is in Bentley, a suburb of Perth in Western Australia. It will operate as a CDMO under the name NovaCina.

NovaCina will manufacture sterile injectable drug products for all phases, from development to full scale commercial production. It has over nine production lines across Oncology/High Potency, Blow-Fill-Seal and multi format vial streams, all supported with 400+ experienced team members. The company plans to expand its service offerings and broaden its expertise with state-of-the-art equipment and analytics.

NovaCina will continue to manufacture oncology drugs and sterile injectable hospital essentials for Pfizer, while it works to extend its customer base and offerings globally.

Bridgewest Perth Pharma, a subsidiary of US-based Bridgewest Group, will oversee and support the continued growth of NovaCina, as well as future investments that broaden and vertically integrate world-class services and products in the life sciences sector.